Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
Conditions
Brief summary
This study will be divided into two parts, Parts A and B and will enroll patients with relapsed/refractory AML or MDS/chronic myelomonocytic leukemia (CMML) patients who have failed up to 2 prior therapeutic regimens. Part A is a dose escalation study to explore the safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) profile of DSP107 when administered in combination with azacitidine (AZA). Part B is a dose escalation study to explore the safety, efficacy, PK and PD profile of DSP107 when administered in combination with AZA and venetoclax (VEN).
Detailed description
Part A is a dose escalation study in up to 4 cohorts of patients designed to test the safety and efficacy of DSP107 administered alone and in combination with AZA. The DSP107 starting dose level in Part A will be 0.3 mg/kg based on aggregate safety, PK and PD data from study DSP107\_001, an ongoing study exploring the safety of escalating DSP107 doses in patients with advanced solid tumors. There will be a single DLT evaluation period, lasting 28 days, to determine the safety of DSP107 in combination with AZA. The safety, efficacy and PK data will be used to establish a recommended Phase II dose for potential future expansion cohorts and a starting dose for Part B. Part B is a dose escalation study in 2 cohorts of patients that will test the safety and efficacy of DSP107 in combination with AZA and VEN. The starting dose for Part B will be at least one dose level lower than the DSP107 dose selected in Part A as being safe and effective in combination with AZA. Once a safe, effective dose has been established in Part B, a recommended phase 2 dose for patients with newly diagnosed AML will be agreed with the FDA at an End-of-Phase 1 meeting.
Interventions
BIOLOGICALDSP107
DSP107 (SIRPα - 4-1BBL) is a bi-functional, trimeric, fusion protein.
DRUGAzacitidine
Azacitidine is an analog of the pyrimidine nucleoside cytidine.
DRUGVenetoclax
Venetoclax is a B-cell lymphoma (BCL)-2 inhibitor
Sponsors
Kahr Medical
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This study will involve sequential enrollment of approximately 36 patients accrued into six dose cohorts, each testing a different DSP107 dose level in combination with azacitidine (Part A) or DSP107 in combination with azacitidine and venetoclax (Part B).
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2 * White Blood Cell count \< 20 x 10\^9/L. * Adequate organ function * Relapsed/refractory AML or MDS/CMML patients who have failed up to 2 prior therapeutic regimens.
Exclusion criteria
* Acute Promyelocytic leukemia * Symptomatic central nervous system (CNS) leukemia or patients with poorly controlled CNS leukemia * Life-threatening (grade 4) immune-mediated adverse event related to prior immunotherapy * Immune-mediated adverse reaction that required discontinuation of prior immunotherapy * Past or current history of autoimmune disease or immune deficiency * History of severe interstitial lung disease or severe pneumonitis or active pneumonitis * Clinically significant and poorly compensated liver disease * Prior organ allografts (such as renal transplant) requiring active immunosuppression * Active graft versus host disease * Treatment with systemic immunostimulatory within 4 weeks prior to initiation of study treatment * Treatment with any CD47/SIRPα targeting agent or immune agonists * Known allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product * Received live, attenuated vaccine within 4 weeks prior to first dose of study treatment * Active Hepatitis B or C infection * History or evidence of any other clinically unstable/uncontrolled disorder, condition, or disease * Pregnant or breast feeding or planning to become pregnant while enrolled in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events (AEs) | Duration of the study, estimated to be 12 months | An AE is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. |
| Dose Limiting Toxicities (DLT) | At the end of Treatment Cycle 2 (within 2 months of treatment initiation) | A DLT is defined as a clinically significant AE or laboratory abnormality that is related to DSP107 or the combination of DSP107 and AZA, but is unrelated to disease progression, intercurrent illness or concomitant medications |
| Response Rate (RR) including Complete Remission (CR) and Complete Remission with Incomplete Blood Count Recovery (CRi) | Within 6 months of treatment initiation | Response rates will be determined by assessing peripheral blood and bone marrow samples. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 4-week Mortality Rate | Within 4 weeks of treatment initiation | The proportion of patients who die within 4 weeks of treatment initiation. |
| DSP107 Serum Concentration | Duration of the study, estimated to be 12 months | Serum samples will be collected to determine circulating levels of DSP107. |
| Overall Response Rate (ORR) | Within 6 months of treatment initiation | Peripheral and bone marrow samples will be assessed to determine ORR. The ORR will measure the proportion of patients who achieve CR, CRi, complete remission with incomplete hematological recovery (CRh), complete remission with incomplete platelet recovery (CRp) or partial response (PR) within 6 months of treatment initiation, with or without cytogenetic response, hematological improvements and a morphologic leukemia-free state. |
| Change in Phenotypic and Activation Profiles of Peripheral Blood Mononuclear Cells | Duration of the study, estimated to be 12 months | Whole blood samples will be collected throughout the study for immunophenotyping by flow cytometry and/or mass cytometry. |
| DSP107 anti-drug antibody (ADA) formation | Duration of the study, estimated to be 12 months | Serum samples will be collected throughout the study for assessment of ADA formation using validated assay. |
| Morphologic Leukemia-Free (MLF) Rate | Within 6 months of treatment initiation | Peripheral and bone marrow samples will be assessed to determine the proportion of patients who are morphologically leukemia-free within 6 months of treatment initiation. |
| Minimal Residual Disease (MRD) Status | Duration of the study, estimated to be 12 months | Peripheral and bone marrow samples will be assessed to determine minimal residual disease (MRD) status at response and/or the best MRD response during study participation. |
Countries
United States
Outcome results
None listed